June 22
2:00 pm - 3:00 pm EDT


Life sciences dealmaking faces more antitrust scrutiny

The US Federal Trade Commission has stepped up antitrust enforcement in life sciences by seeking to block acquisitions led by Illumina and Amgen, with more deals at risk. Endpoints News will examine the origins, impacts and likely legacy of these antitrust policies.

register now
register for the webinar

No cost to register, subject to confirmation

By registering for this event, you accept that you may receive direct communication from the sponsor(s).

If you are experiencing problems with your registration, please try the Zoom registration page.

Jeny M. Maier

Jeny M. Maier

Partner, Axinn, Veltrop & Harkrider LLP

Jeny Maier guides major corporations through large, strategic M&A transactions, using her significant experience to advise on pre-merger notification requirements and substantive competitive issues. Jeny helps clients navigate antitrust issues throughout the life cycle of a transaction, from initial risk analysis and due diligence, to negotiating merger agreement terms, through antitrust agency review, investigation and, where needed, remedies. She also regularly counsels clients who are third parties contacted by the antitrust agencies in connection with merger investigations. Described in Who’s Who Legal as a “great competition lawyer with strong expertise in merger cases” and the “knowledge and ability to provide clear and prescient insight” in to the competition world, Jeny is a sought-after antitrust advocate.

Jared Whitlock

Jared Whitlock


Jared Whitlock is the features editor at Endpoints. Previously a freelance journalist and MIT knight science journalism fellow in fall 2021, his work has appeared in publications like WIRED, STAT and The New York Times. Prior to this, he was a biotech, healthcare and special projects reporter at The San Diego Business Journal. When not fussing over words, he can be find surfing at various San Diego beaches.